A 64-year-old woman in Mumbai has been diagnosed with Guillain-Barre Syndrome, marking the city's first case of this rare nerve disorder. After being hospitalized with fever and ascending paralysis, ...

Mumbai reported its first case of Guillain-Barre Syndrome (GBS) on Friday after a 64-year-old woman was diagnosed with the ...

Mumbai reported its first case of Guillain-Barre Syndrome (GBS) on Friday after a 64-year-old woman was diagnosed with the rare nerve disorder, civic officials said. GBS is a rare condition in which a ...

Background: Refractory chronic inflammatory demyelinating polyneuropathy (CIDP) is a challenging subset of CIDP. It does not respond well to immune therapy and causes substantial disability. A ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...

DAVENPORT & Co LLC reduced its position in shares of argenx SE (NASDAQ:ARGX – Free Report) by 5.1% during the fourth quarter, ...

BOSTON—Crystal Adam, President of Research & Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), recently sold a total of ...

BOSTON—Barbara Weber, the Chief Executive Officer of Tango Therapeutics, Inc. (NASDAQ:TNGX), a $350 million market cap biotech company, recently sold a portion of her holdings in the company.

Patients with ATTR-PN have a high rate of comorbidities and substantial direct healthcare and economic burdens, a study found.

GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been ...

BofA raised the firm’s price target on Argenx (ARGX) to $774 from $770 and keeps a Buy rating on the shares. The company pre-announced Q4 ...